Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
Marion Plaze, David Attali, Matthieu Prot, Anne‐Cécile Petit, Michael Blatzer, Fabien Vinckier, Laurine Levillayer, Jeanne Chiaravalli, Florent Perin-Dureau, Arnaud Cachia, Gérard Friedlander, Fabrice Chrétien, Etienne Simon‐Lorière, Raphaël Gaillard
Topics & Concepts
ChlorpromazineIC50A549 cellPharmacologyCoronavirusIn vitroVirologyCytopathic effectMedicineVirusDrugCell cultureBiologyChemistryInternal medicineCoronavirus disease 2019 (COVID-19)BiochemistryDiseaseInfectious disease (medical specialty)GeneticsPharmacological Receptor Mechanisms and EffectsPhenothiazines and Benzothiazines Synthesis and ActivitiesLong-Term Effects of COVID-19